Priorities for CMV vaccine development - sprookjes - yvandenbroek - TriplyDB

Priorities for CMV vaccine development

Priorities for CMV vaccine development

http://www.wikidata.org/entity/Q36216553

about

Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.Controlling cytomegalovirus: helping the immune system take the lead Immune biomarkers predictive of respiratory viral infection in elderly nursing home residents.Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies Reduced frequencies of polyfunctional CMV-specific T cell responses in infants with congenital CMV infection Inhibition of cytomegalovirus infection and photothermolysis of infected cells using bioconjugated gold nanoparticles High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination.A dynamic transmission model with age-dependent infectiousness and reactivation for cytomegalovirus in the United States: Potential impact of vaccination strategies on congenital infection.The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection.Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand Type 1 Interferons and NK Cells Limit Murine Cytomegalovirus Escape from the Lymph Node Subcapsular Sinus.Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?Awareness of Cytomegalovirus Infection among Pregnant Women in Geneva, Switzerland: A Cross-sectional Study.Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.Longitudinal Kinetics of Cytomegalovirus-Specific T-Cell Immunity and Viral Replication in Infants With Congenital Cytomegalovirus Infection.Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection aga Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection The Human Cytomegalovirus UL116 Gene Encodes an Envelope Glycoprotein Forming a Complex with gH Independently from gL Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.An Attenuated CMV Vaccine with a Deletion in Tegument Protein GP83 (pp65 Homolog) Protects against Placental Infection and Improves Pregnancy Outcome in a Guinea Pig Challenge Model.Congenital Cytomegalovirus: a "Now" Problem-No Really, Now Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?Molecular and biological characterization of a new isolate of guinea pig cytomegalovirus.Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4+ and CD8+ T Cell Responses against Mouse Cytomegalovirus Infection.Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission.Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.High-throughput screening of a GlaxoSmithKline protein kinase inhibitor set identifies an inhibitor of human cytomegalovirus replication that prevents CREB and histone H3 post-translational modification.Congenital Human Cytomegalovirus Infection and the Enigma of Maternal Immunity.Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections.Chemokines encoded by herpesviruses.Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.Strong Cell-Mediated Immune Response to Human Cytomegalovirus Is Associated With Increased Risk of Fetal Infection in Primarily Infected Pregnant Women.Cloning, Assembly, and Modification of the Primary Human Cytomegalovirus Isolate Toledo by Yeast-Based Transformation-Associated Recombination.Breast Milk HCMV viral load is associated with the establishment of breast milk CMV-pp65-specific CD8 T cells in Human CMV infected Mothers.Congenital Cytomegalovirus Infection: Improved Understanding of Maternal Immune Responses That Reduce the Risk of Transplacental Transmission.Cytomegalovirus vaccines under clinical development

P2860

Q21089588-D1668A15-76D1-4E74-B505-3D0010C0E708 Q27692570-91920E3B-CAF6-4922-B8FA-1A79B5584AC6 Q33820695-86378AE9-9B2F-442D-8B0A-ECDFBA4FE3E6 Q34282272-25F884D9-271C-47DF-8009-87B8F7BF6908 Q34753135-E5C893AE-7509-4F31-B6BD-3C29C9989A53 Q35196400-39CCAB30-B3C3-498F-A730-CF4EAEE9DDFB Q35200495-E568E435-E19D-475D-9658-268AA6F5BFD8 Q35861195-7BB1B72D-4A31-4E6A-8013-834E4D6D7CB7 Q35886919-87BB8E9C-9764-4050-B90B-B80B4502024E Q36135817-D0BF0600-B9B4-4135-9D7B-96DEA3DFDFD9 Q36210368-E5A886F7-F5CF-42A5-9468-72DDB4716128 Q36215037-5639B450-DFEF-4288-BF41-74EB8E60F15D Q36281094-2F2A29EE-7D21-49B1-89C4-58F1D8865169 Q36302615-EA8377A6-F2D4-4849-B708-B65B0C150A8A Q36403590-ABB8D059-F241-4CCC-B75B-B22A82EEBEC8 Q36430938-B486DA24-F783-4F6C-91EC-8CA9A3AAA1AC Q36612933-EBC62E91-46BE-490B-8AA0-C7A569546AE3 Q36633558-44BFBCA1-E7AA-473E-92C2-BCBB87277361 Q36830632-9449713B-7AAA-4B76-A2EB-144D6B6D9781 Q36878894-F2468AC2-6FF4-42CA-8FB5-334B2EEAED07 Q36977623-B1C9C9BB-7CB1-4063-9898-7D2229482DB8 Q37203522-2C9831B4-7558-4EA9-AE9B-D366FBEAD052 Q37409233-7FD6CF07-4BC8-488C-854A-F6DCF0843AAC Q37508272-6F08788F-BDB8-4688-8219-5F4D51800EA5 Q37563598-717BCCFC-7FBA-4910-98A0-50987B7B93A3 Q37574334-4F8B17AD-FE47-4EBC-BE14-D26E1D116016 Q37611802-0222DA53-56D8-46A8-884F-DEA69DC04193 Q37651700-5DDD4442-A292-4725-9431-267F36BF6928 Q38744569-405788C3-A835-4641-80D1-DB0ED8703586 Q38835171-71EF2AF8-A255-4CF3-A573-2426761FA74B Q39013996-BF2D67CC-64AE-44B5-A329-D24DC4C099CA Q39296561-57598378-168C-4CD6-A6F2-55ED1C3FF607 Q40059344-266A556D-805F-471A-957C-F16D92071F2B Q40067378-B0185414-6AE2-4EE0-BA46-DB1CAD5A2C78 Q40295939-BCB78AAA-4945-4F9D-A3B9-14D74470B170 Q41107880-01E2CA7D-2822-4E0E-9473-4EB0F967B40C Q41921793-6F53680E-DE64-4155-9427-EA1B804D5FB6 Q41926403-33DA8946-A42C-4C67-B449-5812DDD470E3 Q41987283-53AAB9F4-8267-4D8E-8585-0EE54CC113C9 Q42380888-F690E2FF-D53F-4D79-8844-4484B7CD7A9F

P2860

Priorities for CMV vaccine development

http://www.wikidata.org/entity/Q36216553

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Priorities for CMV vaccine development

@ast

Priorities for CMV vaccine development

@en

type

label

Priorities for CMV vaccine development

@ast

Priorities for CMV vaccine development

@en

prefLabel

Priorities for CMV vaccine development

@ast

Priorities for CMV vaccine development

@en

P1433

Q36216553-B1816F9E-4DAA-40D8-9DFF-1D985AC984CA

P1476

Q36216553-C74FEB67-87A2-4223-9106-2B2A4D862E74

P2093

Q36216553-2367301E-D097-4D01-8BE7-4B466E61FB0A

Q36216553-33F90894-B6CE-46FD-8875-913191999C43

Q36216553-68462A13-977D-433F-9BE4-4B0A2E356F30

Q36216553-6C19D351-2707-4509-A480-63D9A26CBD43

Q36216553-725A1A10-4FE4-4704-9EEE-E4D1D614D5CE

Q36216553-79F378E9-EB07-447E-9536-E8478E17383C

Q36216553-82E5A11D-13FE-4854-B037-6950F0FEC436

Q36216553-EF89BBD0-AE08-406D-8CCA-3D3F55D4396F

Q36216553-FBF4BA98-9EFF-4840-B1AB-ADCAE6B80B9C

P2860

Q36216553-05661C75-EDD5-4D2A-B996-173FBD03CA6D

Q36216553-08008CC4-AFC5-47D3-A754-DD5FCA338CEF

Q36216553-1E8ACCC5-A0F5-41A6-9B71-70305A31FC03

Q36216553-1F05D470-A202-4A5D-8217-D239C3108FE2

Q36216553-257D769D-EB23-44DA-952F-8383A9210208

Q36216553-37342D17-5902-470F-BFB4-7E1145949D08

Q36216553-419FA151-4615-4F53-8375-D8A30F6A713E

Q36216553-46F9AB36-3B13-4C5F-AF68-6F7EFFBB16BA

Q36216553-4B4FD2DF-79BF-402D-936A-DF3FA2028176

Q36216553-4C9CC1CF-8752-4263-9686-47E83B0B8739

P304

Q36216553-C33DFAA2-B1C3-4F8A-818E-6C6A86D9FE67

P31

Q36216553-21EFBAD5-00C0-431C-9E47-111FFFD40195

P356

Q36216553-9A7DDEAE-B575-4618-8C24-63690E374A83

P407

Q36216553-B38018A1-0900-4C15-A83E-222130B71E07

P433

Q36216553-CB4C0371-5B29-4D8E-8493-9796CDE9B8D4

P478

Q36216553-817FD15B-2685-46EB-BAC6-A258C23B9188

P50

Q36216553-B04E4AC0-8CC1-4876-812C-187BD0985926

Q36216553-EF6EE461-9ED1-4BC7-BCFB-40C63D191C53

P577

Q36216553-A8B17C47-7005-4E2D-8644-C447983D63A9

P698

Q36216553-AB11002D-F954-4347-8434-5861D597B54A

P932

Q36216553-73151269-1763-4B89-A40A-BC1CCC9D3975

P356

J.VACCINE.2013.09.042

P1433

P1476

Priorities for CMV vaccine development

@en

P2093

Catherine A Laughlin

http://www.w3.org/2001/XMLSchema#string

Edward S Mocarski

http://www.w3.org/2001/XMLSchema#string

Jennifer S Read

http://www.w3.org/2001/XMLSchema#string

Mark R Schleiss

http://www.w3.org/2001/XMLSchema#string

Paul D Griffiths

http://www.w3.org/2001/XMLSchema#string

Per Ljungman

http://www.w3.org/2001/XMLSchema#string

Robert F Pass

http://www.w3.org/2001/XMLSchema#string

Stephanie R Bialek

http://www.w3.org/2001/XMLSchema#string

Suresh B Boppana

http://www.w3.org/2001/XMLSchema#string

P2860

New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection

Vaccine prevention of maternal cytomegalovirus infection

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

Incidence of cytomegalovirus infection among the general population and pregnant women in the United States.

Cytomegalovirus infection of extremely low-birth weight infants via breast milk.

Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality.

Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States.

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee.

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.

P304

4-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2013.09.042

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Philip R Krause

Stanley Plotkin

P577

2013-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24129123

http://www.w3.org/2001/XMLSchema#string

P932

4623576

http://www.w3.org/2001/XMLSchema#string